Drug Trial Radar · NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
387
Planned (sponsor's estimate)
Start
Jan 23, 2019
Primary completion
Mar 30, 2033
Study completion Jun 16, 2033
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Dec 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer
Conditions
- Multiple Myeloma
Interventions
LinvoseltamabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation periodTime frame: Up to 28 days
- Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Up to 5 years
- Incidence and severity of adverse events of special interest (AESI)Time frame: Up to 5 years
- Assessment of the pharmacokinetics (PK) of linvoseltamabTime frame: Up to 5 years
- Concentrations of linvoseltamab in serum over timeTime frame: Up to 5 years
- Objective response rate (ORR) as determined by an Independent Review Committee (IRC)Time frame: Up to 5 years
- Incidence and severity of cytokine release syndrome (CRS) with linvoseltamabTime frame: Up to 5 years
- ORR of IV linvoseltamab as assessed by investigatorTime frame: Up to 5 years
Locations
40 sites in 7 countries. Site status is shown where the registry gives one.
Sylvester Comprehensive Cancer Center
Miami, Florida · Active not recruiting
Moffitt Cancer Center - McKinley Drive
Tampa, Florida · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Indiana University_Michigan Street
Indianapolis, Indiana · Active not recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
C. S. Mott_University of Michigan
Ann Arbor, Michigan · Active not recruiting
Barbara Ann Karmanos Cancer Center
Detroit, Michigan · Active not recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Active not recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Active not recruiting
Ohio State University James Cancer Hospital
Columbus, Ohio · Recruiting
Oregon Health and Science University (OHSU) Marquam Hill Campus
Portland, Oregon · Recruiting
University of Texas MD Anderson Clinic
Houston, Texas · Active not recruiting
Swedish Cancer Institute
Seattle, Washington · Recruiting
ZNA Psychiatrisch Ziekenhuis Stuivenberg
Antwerp, Belgium · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Completed
Universitatsklinikum Wurzburg
Würzburg, Germany · Completed
Universitatsklinikum Essen
Essen, North Rhine-Westphalia, Germany · Completed
Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR
Mainz, Rhineland-Palatinate, Germany · Completed
Keio University Hospital
Tokyo, Japan · Recruiting
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, Japan · Completed
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan · Recruiting
Gunma University Hospital
Maebashi, Gunma, Japan · Recruiting
Ibaraki Prefectural Central Hospital
Kasama-shi, Ibaraki, Japan · Recruiting
University Hospital Kyoto Prefectural Univ of Medicine
Kyoto, Kyoto, Japan · Recruiting
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan · Completed
Tokushima Prefectural Central Hospital
Tokushima, Tokushima, Japan · Recruiting
Japanese Red Cross Medical Center
Shibuya-ku, Tokyo, Japan · Completed
National Cancer Center Korea
Goyang, South Korea · Recruiting
Seoul National University Cancer Hospital
Seoul, South Korea · Recruiting
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea · Recruiting
Yonsei University College of Medicine, Severance Hospital
Seoul, South Korea · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Clinico Universitario de Salamanca
Salamanca, Spain · Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Universitary Hospital La Princesa
Madrid, Salamanca, Spain · Recruiting
Royal Marsden Hospital
Sutton, Surrey, United Kingdom · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.